Category: Press Releases

Collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC).

Company overview to highlight novel gene therapies for cancer and diabetes

Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib

Investor presentation to highlight novel gene therapies for cancer and diabetes

Investor presentations to highlight novel gene therapies for cancer and diabetes

Genprex has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct offering priced at-the-market under Nasdaq rules.

World reknowned medical and clinical experts to guide Genprex’ novel gene therapy clinical development programs in cancer and diabetes, including its two upcoming clinical trials in lung cancer

Joins Global Movement to Raise Awareness and Reduce the Burden of Cancer Worldwide

Major milestones achieved in advancing gene therapies for lung cancer and diabetes

Company to provide update on upcoming clinical trials for the treatment of non-small cell lung cancer and an overview of its diabetes gene therapy